Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR

Healthcare Psychedelics
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

60 Minutes: Psychedelics Could Help People with Addiction and Anxiety

Livemoney August 18, 2020

Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

PR Newswire August 14, 2020

MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President

Canada NewsWire August 13, 2020

This Landmark Decision is a Major Game Changer for Companies Focused on Psylocybin

Livemoney August 10, 2020

Venture Company Investor Presentations Now Available for On-Demand Viewing

Canada NewsWire August 10, 2020

MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Canada NewsWire August 6, 2020

Live Investor Conference & Webinar: Venture Companies Present August 6th

Canada NewsWire August 3, 2020

MindMed Completes Dosing 18-MC Phase 1 Study

Canada NewsWire July 28, 2020

MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

Canada NewsWire June 26, 2020

MindMed Developing IP For Personalized Psychedelic Assisted Therapies

Canada NewsWire June 24, 2020

These are Some of The Top Companies to Watch in the Booming Psychedelics Industry

Livemoney June 18, 2020

MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

PR Newswire June 18, 2020

The Top Healthcare Bullboards: April - June 2020

Stockhouse Editorial June 17, 2020

Psychedelics Quickly Creating a Potential $100 Billion Market Opportunity

Livemoney June 12, 2020

These Companies Want to Give You LSD to Treat a Range of Mental Health Issues

Livemoney June 9, 2020

New Psychedelics Stocks and Acquisitions

Omri Wallach June 8, 2020

Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients

PR Newswire June 8, 2020

MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders

Canada NewsWire June 4, 2020

Psilocybin: The Weight Loss Secret We've Been Searching For?

Livemoney June 4, 2020

MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

Canada NewsWire June 2, 2020